• Kenneth Philbrick, Ph.D. candidate

    Type Size

    Kenneth Philbrick, Ph.D. candidate

    Institution: Oregon State University

    Career Stage: Member in training (Ph.D. Candidate)

    Research Focus: Effects of leptin on normal bone metabolism and osteolysis in rodents.

    ASBMR committee/leadership positions held: Young Investigator Subcommittee

    How does your research make a difference?

    Bone metabolism is sensitive to physiological changes in energy balance. Understanding how energy balance exerts skeletal effects is critical for the prevention and treatment of skeletal disorders relating to malnutrition, obesity, and weight loss. Leptin is a hormone that is produced by body fat and that typically circulates in levels relative to total fat mass. My research is investigating the skeletal actions of leptin during growth and the potential action of the hormone as a mediator of inflammatory osteolysis. A better understanding of how leptin affects bone could suggest new treatments to mediate skeletal pathologies associated with orthopedic bone loss, obesity, rapid weight loss, and possibly osteoporosis. 

    What has been your favorite ASBMR Annual Meeting moment?

    ASBMR is a fantastic meeting!! I look forward to attending it each year.  I love how ASBMR brings everyone together to share science and, at the same time, more than a few laughs. As a member in-training, a real meeting highlight has been finding myself at the poster sessions, presenting data, and standing, on more than one occasion, next to a fellow researcher doing similar work. These impromptu interactions have been truly illuminating and fantastic ASBMR moments for me.

    What are your hopes for your own career and the bone field at large?

    There are numerous major skeletal diseases and disorders that remain poorly understood and/or for which there are few good treatment options. I hope that through my personal research, and the work of our broader community, major advances in the ability to prevent, diagnose, and treat skeletal disorders will continue to be made.